Anaptysbio (ANAB) Income from Non-Controlling Interests (2021 - 2026)
Anaptysbio (ANAB) posted Income from Non-Controlling Interests of -$122000.0 for Q1 2026, down 71.83% on a QoQ basis from -$71000.0 in Q4 2025, and up 15.28% year-over-year from -$105831.3 in Q1 2025.
Anaptysbio (ANAB) Income from Non-Controlling Interests (2021 - 2026) Analysis & Trends
Anaptysbio's Income from Non-Controlling Interests history runs 6 years deep, the most recent figure standing at -$122000.0 for Q1 2026.
- Quarterly Income from Non-Controlling Interests rose 15.28% year-over-year to -$122000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$307000.0 (down 139.11% YoY) and the FY2025 annual result came in at -$329000.0, down 129.85% from the prior year.
- Income from Non-Controlling Interests was -$122000.0 for Q1 2026 at Anaptysbio, down from -$71000.0 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $2.0 million in Q1 2023 and bottomed at -$2.1 million in Q3 2022.
- A 5-year average of $16235.3 and a median of -$71000.0 in 2025 frame the typical range for Income from Non-Controlling Interests.
- Annual changes were most pronounced in 2022 — Income from Non-Controlling Interests slumped 8841.67% — and 2023, when it soared 198.36%.
- Anaptysbio's Income from Non-Controlling Interests stood at $761000.0 in 2022, then soared by 104.07% to $1.6 million in 2023, then plunged by 129.23% to -$454000.0 in 2024, then jumped by 84.36% to -$71000.0 in 2025, then plunged by 71.83% to -$122000.0 in 2026.
- Business Quant data shows ANAB's Income from Non-Controlling Interests at -$122000.0 in Q1 2026, -$71000.0 in Q4 2025, and $53000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,140.12 Bn | 66,139.83 Bn | - | - |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.73 Bn | - | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | - |
| 4 | BeOne Medicines | 472.60 Bn | 467.81 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 122.34 Bn | 115.09 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 70.14 Bn | 61.39 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.79 Bn | 62.79 Bn | - | - |
| 8 | Argenx Se | 56.19 Bn | 51.00 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn | - |
| 10 | Anaptysbio | 1.58 Bn | 1.29 Bn | - | -122,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -122,000.00 |
| Dec 31, 2025 | -71,000.00 |
| Sep 30, 2025 | 53,000.00 |
| Jun 30, 2025 | -167,000.00 |
| Mar 31, 2025 | -144,000.00 |
| Dec 31, 2024 | -454,000.00 |
| Sep 30, 2024 | 1.17 Mn |
| Jun 30, 2024 | 209,000.00 |
| Mar 31, 2024 | 173,000.00 |
| Dec 31, 2023 | 1.55 Mn |
| Sep 30, 2023 | 1.26 Mn |
| Jun 30, 2023 | -344,000.00 |
| Mar 31, 2023 | 1.98 Mn |
| Dec 31, 2022 | 761,000.00 |
| Sep 30, 2022 | -2.15 Mn |
| Jun 30, 2022 | -1.43 Mn |
| Mar 31, 2022 | -2.01 Mn |
| Sep 30, 2021 | -24,000.00 |
| Jun 30, 2021 | -65,000.00 |
| Mar 31, 2021 | -107,000.00 |